Back to Search
Start Over
Everolimus-eluting bioresorbable scaffolds and metallic stents in diabetic patients: a patient-level pooled analysis of the prospective ABSORB DM Benelux Study, TWENTE and DUTCH PEERS.
- Source :
-
Cardiovascular diabetology [Cardiovasc Diabetol] 2020 Oct 02; Vol. 19 (1), pp. 165. Date of Electronic Publication: 2020 Oct 02. - Publication Year :
- 2020
-
Abstract
- Background: Several studies compared everolimus-eluting bioresorbable scaffolds (EE-BRS) with everolimus-eluting stents (EES), but only few assessed these devices in patients with diabetes mellitus.<br />Aim: To evaluate the safety and efficacy outcomes of all-comer patients with diabetes mellitus up to 2 years after treatment with EE-BRS or EES.<br />Methods: We performed a post hoc pooled analysis of patient-level data in diabetic patients who were treated with EE-BRS or EES in 3 prospective clinical trials: The ABSORB DM Benelux Study (NTR5447), TWENTE (NTR1256/NCT01066650) and DUTCH PEERS (NTR2413/NCT01331707). Primary endpoint of the analysis was target lesion failure (TLF): a composite of cardiac death, target vessel myocardial infarction or clinically driven target lesion revascularization. Secondary endpoints included major adverse cardiac events (MACE): a composite of all-cause death, any myocardial infarction or clinically driven target vessel revascularization, as well as definite or probable device thrombosis (ST).<br />Results: A total of 499 diabetic patients were assessed, of whom 150 received EE-BRS and 249 received EES. Total available follow-up was 222.6 patient years (PY) in the EE-BRS and 464.9 PY in the EES group. The adverse events rates were similar in both treatment groups for TLF (7.2 vs. 5.2 events per 100 PY, p = 0.39; adjusted hazard ratio (HR) = 1.48 (95% confidence interval (CI): 0.77-2.87), p = 0.24), MACE (9.1 vs. 8.3 per 100 PY, p = 0.83; adjusted HR = 1.23 (95% CI: 0.70-2.17), p = 0.47), and ST (0.9 vs. 0.6 per 100 PY, p > 0.99).<br />Conclusion: In this patient-level pooled analysis of patients with diabetes mellitus from 3 clinical trials, EE-BRS showed clinical outcomes that were quite similar to EES.
- Subjects :
- Aged
Cardiovascular Agents adverse effects
Clinical Trials as Topic
Coronary Artery Disease diagnostic imaging
Coronary Artery Disease mortality
Everolimus adverse effects
Female
Humans
Male
Middle Aged
Percutaneous Coronary Intervention adverse effects
Prosthesis Design
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Absorbable Implants
Cardiovascular Agents administration & dosage
Coronary Artery Disease therapy
Diabetes Mellitus diagnosis
Diabetes Mellitus mortality
Drug-Eluting Stents
Everolimus administration & dosage
Percutaneous Coronary Intervention instrumentation
Subjects
Details
- Language :
- English
- ISSN :
- 1475-2840
- Volume :
- 19
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Cardiovascular diabetology
- Publication Type :
- Academic Journal
- Accession number :
- 33008407
- Full Text :
- https://doi.org/10.1186/s12933-020-01116-2